Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

npj Parkinsons Disease is a leading open-access journal dedicated to advancing research in the field of Parkinson's disease and related neurodegenerative disorders. Published by NATURE PORTFOLIO, this journal has been on the forefront of scientific inquiry since its inception in 2015, providing a high-quality platform for the dissemination of groundbreaking research. The journal's reputation is underscored by its impressive Q1 rankings in Cellular and Molecular Neuroscience and Neurology categories, as well as its commendable positions in Scopus rankings, placing it within the top echelons of neuroscience and clinical neurology research. With its focus on innovative methodologies and translational studies, npj Parkinsons Disease aims to foster collaboration among researchers, clinicians, and healthcare professionals, ultimately contributing to the improved understanding and treatment of Parkinson's disease. Researchers, professionals, and students are encouraged to explore its rich repository of knowledge, accessible freely since its launch, to stay abreast of the latest developments in this critical area of neuroscience.

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

LUTS - Lower Urinary Tract Symptoms is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of urology and neurology with a special focus on lower urinary tract dysfunctions. Since its inception in 2010, the journal has established itself as an essential resource for researchers and practitioners, featuring cutting-edge research articles, reviews, and clinical studies that explore the complexities of lower urinary tract symptoms and their neurological implications. Housed in Japan, LUTS occupies an important niche in the academic landscape, currently ranked Q2 in Urology and Q3 in Neurology, and holding notable Scopus ranks within both fields. The journal serves as a platform for disseminating innovative ideas and fostering collaborative efforts among experts, making significant contributions to improve patient care and outcomes. With its commitment to high-quality scholarship, LUTS is an indispensable tool for those seeking to stay at the forefront of research in urology and neuroscience.

MOVEMENT DISORDERS, published by Wiley, stands as a premier outlet for cutting-edge research in the field of neurology, particularly focusing on the various aspects of movement disorders. With both its ISSN (0885-3185) and E-ISSN (1531-8257) identifiers, this journal is at the forefront of neurological research, holding a remarkable impact factor and recognized in the top quartiles (Q1) of the disciplines of Neurology and Clinical Neurology as of 2023. The journal boasts an impressive Scopus ranking, placing it in the top 8 out of 192 for Neuroscience-Neprology and 19 out of 400 for Medicine-Clinical Neurology, reflecting its high relevance and influence in the field. Released quarterly since its inception in 1986 and continuing through 2024, MOVEMENT DISORDERS publishes a mix of original research articles, reviews, and case reports that catalyze innovation and foster collaboration among researchers, healthcare professionals, and students dedicated to understanding and treating movement disorders. As a non-open access journal, it nevertheless offers valuable insights that are essential for the advancement of knowledge in neurology, making it a critical resource for anyone invested in this challenging and evolving field.

Clinical and Experimental Gastroenterology is a prestigious Open Access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of gastroenterology through rigorous research and innovative insights. With its ISSN 1178-7023, the journal has established a significant presence since its inception in 2008 and has been actively contributing to the academic landscape from New Zealand. The journal has attained a commendable Q2 rank in the Gastroenterology category as of 2023, placing it in the upper-tier percentile of similar journals. It currently ranks #57 out of 167 in the Scopus database, highlighting its relevance and impact in the field at the 66th percentile. Encompassing a wide range of topics within gastroenterology, the journal aims to foster discussion and disseminate findings that enhance clinical practices and patient care. Researchers, healthcare professionals, and students alike will find this journal an invaluable resource for cutting-edge research and developments in gastrointestinal health.